Sio Gene Therapies is a a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. Co. has three clinical-stage programs: AXO-AAV-GM1 for the treatment of GM1 gangliosidosis; AXO-AAV-GM2 for the treatment of GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases); and AXO-Lenti-PD for the treatment of Parkinson's disease. The SIOX stock yearly return is shown above.
The yearly return on the SIOX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SIOX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|